Sustainable growth driven by 3 global products and 3 next-generation products
First written in FY2016-Q3. 24 of 37 entries say "Advanced", first in FY2018. Latest entry: 2026-08-04.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「The main factors were increased sales in the Medical business of Rexulti, an antipsychotic positioned as a growth driver under the Fourth Medium-Term Management Plan, as well as the long-acting injectable Abilify Asimtufii, JINARC and other products.」
It identifies increased sales of Abilify Asimtufii, JINARC and other products, in addition to Rexulti, as growth drivers under the Fourth Medium-Term Management Plan. - FY2024ReframedAnnual report
「The main factors were increases in the Medical business from the ‘Core 2’ products positioned as growth drivers under the Fourth Medium-Term Management Plan, the antipsychotic Rexulti and antineoplastic Lonsurf, as well as the long-acting antipsychotics Abilify Maintena and Abilify Asimtufii, the V2-receptor antagonist JINARC and other products.」
Under the Fourth Medium-Term Management Plan, the framework changed from the previous focus on the 4 global products to one that explicitly identifies Rexulti and Lonsurf as the ‘Core 2’ products. - FY2024-H1ReframedAnnual report
「The main factors were increases in the Medical business from the ‘Core 2’ products positioned as growth drivers under the Fourth Medium-Term Management Plan, the antipsychotic Rexulti and antineoplastic Lonsurf, as well as the long-acting antipsychotics Abilify Maintena and Abilify Asimtufii, the V2-receptor antagonist JINARC and other products.」
The framework is changing under the Fourth Medium-Term Management Plan from the previous focus on the 4 global products as growth drivers to one that explicitly identifies Rexulti and Lonsurf as the ‘Core 2’ products. - FY2024-Q1AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotics Abilify Maintena/Abilify Asimtufii, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥199.741 billion, up 25.1% year on year.」
The 4 global products, which are growth drivers under the Third Medium-Term Management Plan, recorded revenue up 25.1% year on year. - FY2023AdvancedAnnual report
「In the healthcare business, the 4 global products, which are growth drivers, grew substantially from the previous fiscal year.」
The 4 global products, which are growth drivers under the Third Medium-Term Management Plan, achieved full-year revenue of ¥726,850 million, up 17.4% year on year. - FY2023-Q3AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥527.977 billion, up 16.2% year on year.」
Total revenue from the 4 global products, positioned as growth drivers for sustainable growth, increased 16.2% year on year, demonstrating the growth achieved by the product group. - FY2023-Q2AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥337.138 billion, up 15.8% year on year.」
Total revenue from the 4 global products, which are growth drivers under the Third Medium-Term Management Plan, increased 15.8% year on year, demonstrating the growth achieved by the key product group. - FY2023-Q1AdvancedAnnual report
「Combined revenue from the four products that the Group classifies as global products—long-acting antipsychotic Abilify Maintena, antipsychotic Rexulti, V2-receptor antagonists Samsca/JINARC, and antineoplastic agent Lonsurf—was ¥159.678 billion, up 17.8% year on year.」
Total revenue from the 4 global products, positioned as growth drivers for sustainable growth, increased 17.8% year on year. - FY2022AdvancedAnnual report
「Combined revenue from the four products designated by our Group as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥619,187 million, up 26.4% from the previous fiscal year.」
Revenue from the 4 global products, which are growth drivers under the Third Medium-Term Management Plan, increased 26.4% from the previous fiscal year, demonstrating the growth achieved by the key product group. - FY2022-Q3AdvancedAnnual report
「Total revenue from the Group's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 26.0% year on year to ¥454,498 million.」
Total revenue from the 4 global products was ¥454,498 million, up 26.0% year on year, demonstrating the performance of the growth drivers. - FY2022-Q2AdvancedAnnual report
「Combined revenue from the four products designated by our Group as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥291,165 million, up 23.4% year on year.」
Total revenue from the 4 global products, positioned as growth drivers for sustainable growth, increased 23.4% year on year, demonstrating the growth achieved by the product group. - FY2022-Q1AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥135,602 million, up 18.0% year on year.」
Total revenue from the 4 global products, the existing growth drivers, increased 18.0% year on year, demonstrating the product group's performance toward sustainable growth. - FY2021AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥489,837 million, up 14.0% from the previous fiscal year.」
The company continued to position the existing 4 global products as growth drivers under the Third Medium-Term Management Plan, and their total revenue increased 14.0% from the previous fiscal year. - FY2021-Q3AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥360,850 million, up 10.9% year on year.」
Total revenue from the 4 global products increased 10.9% year on year, demonstrating their performance as growth drivers under the Third Medium-Term Management Plan. - FY2021-Q2AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥235,975 million, up 8.0% year on year.」
Total revenue from the 4 global products, which are growth drivers under the Third Medium-Term Management Plan, was ¥235,975 million, up 8.0% year on year. - FY2021-Q1AdvancedAnnual report
「Combined revenue from the four products designated by the Company as global products—Abilify Maintena, a long-acting antipsychotic; Rexulti, an antipsychotic; Samsca/Jinarc, a V2-receptor antagonist; and Lonsurf, an antineoplastic—was ¥114,918 million, up 4.3% year on year.」
Total revenue from the 4 global products, positioned as growth drivers under the Third Medium-Term Management Plan, was ¥114,918 million, up 4.3% year on year. - FY2020AdvancedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 14.5% from the previous fiscal year to ¥429,714 million.」
Total revenue from the 4 global products was ¥429,714 million, up 14.5% from the previous fiscal year, demonstrating progress by the growth drivers under the Third Medium-Term Management Plan. - FY2020-Q3AdvancedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 20.1% year on year to ¥325,520 million.」
Total revenue from the 4 global products was ¥325,520 million, up 20.1% year on year, demonstrating the growth achieved by the key product group. - FY2020-Q1AdvancedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 36.1% year on year to ¥110,139 million.」
Total revenue from the 4 global products was ¥110,139 million, up 36.1% year on year, demonstrating the growth achieved by the key product group. - FY2019AdvancedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 34.9% from the previous fiscal year to ¥375,133 million.」
Total revenue from the 4 global products was ¥375,133 million, up 34.9% from the previous fiscal year, demonstrating the growth achieved in fiscal 2019. - FY2019-Q3AdvancedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 37.5% year on year to ¥271,046 million.」
Total revenue from the 4 global products was ¥271,046 million, up 37.5% year on year, demonstrating the growth achieved by the key product group. - FY2019-Q2ReframedAnnual report
「Total revenue from the company's 4 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, the V2 receptor antagonists Samsca/JINARC, and the antineoplastic drug Lonsurf, increased 36.6% year on year to ¥173,138 million.」
The product group framework changed from the previous classification of 4 global products and next-generation products to 4 global products including Lonsurf. Total revenue from the 4 products increased 36.6% year on year. - FY2019-Q1AdvancedAnnual report
「Total revenue from the company's 3 global products, the long-acting antipsychotic Abilify Maintena, the antipsychotic Rexulti, and the V2 receptor antagonists Samsca and JINARC, increased 39.7% year on year to ¥72,661 million.」
Total revenue from the 3 global products was ¥72,661 million, up 39.7% year on year, demonstrating the planned growth of the key product group. - FY2018AdvancedAnnual report
「Although revenue from the 3 global products, Abilify Maintena, Rexulti and Samsca/JINARC, grew beyond plan, the external environment surrounding the healthcare business changed more than initially expected due to fundamental reforms to the drug pricing system and measures to promote the use of generic drugs. As a result, revenue was ¥1,292.0 billion under IFRS, against the target of ¥1,440.0 billion under Japanese GAAP, representing an achievement rate of 90%.」
The 3 global products grew beyond plan, with launches and additional indications progressing in key regions, while total revenue under the Second Medium-Term Management Plan reached 90% of its target. - FY2018-Q3RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the Second Medium-Term Management Plan, whose final fiscal year was 2018, and the objective of achieving sustainable growth through 3 global products and next-generation products. - FY2018-Q2RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the objective of achieving sustainable growth through 3 global products and next-generation products under the Second Medium-Term Management Plan. - FY2018-Q1RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and Rexulti and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the objective of achieving sustainable growth through 3 global products and next-generation products under the Second Medium-Term Management Plan. Product names have changed from the previous REXULTI and JINARC designations to Japanese-language designations. - FY2017RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The annual report continues to state the Second Medium-Term Management Plan through fiscal 2018 and the objective of achieving sustainable growth through 3 global products and next-generation products. - FY2017-Q3RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the Second Medium-Term Management Plan through fiscal 2018 and the objective of achieving sustainable growth through 3 global products and next-generation products. - FY2017-Q2RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the Second Medium-Term Management Plan through fiscal 2018 and the objective of achieving sustainable growth through 3 global products and next-generation products. - FY2017-Q1RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the antineoplastic drug Lonsurf as one of its 3 next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The company continues to pursue the Second Medium-Term Management Plan, whose final fiscal year was 2018, and the objective of achieving sustainable growth through 3 global products and 3 next-generation products. - FY2016RestatedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the novel antineoplastic drug Lonsurf as one of its 3 next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
The annual report also explicitly stated the Second Medium-Term Management Plan through fiscal 2018 and the objective of achieving sustainable growth through 3 global products and 3 next-generation products. - FY2016-Q3First statedAnnual report
「Under the Second Medium-Term Management Plan through fiscal 2018, the company positioned the antipsychotic drugs Abilify Maintena and REXULTI and the vasopressin V2 receptor antagonists Samsca and JINARC as its 3 global products, and the novel antineoplastic drug Lonsurf as one of its 3 next-generation products, with the aim of achieving sustainable medium- to long-term growth.」
Under the Second Medium-Term Management Plan through fiscal 2018, the company first identified the objective of achieving sustainable growth through 3 global products and 3 next-generation products.